ArticleProceedings (Baylor University. Medical Center)2019
Pegfilgrastim-induced hyperleukocytosis leading to hospitalization of a patient with breast cancer.
Article in Proceedings (Baylor University. Medical Center), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients.Asia Pacific journal of clinical nutrition · 2024Trial
- A Case of Concurrent Leukocytosis and Systemic Capillary Leak Syndrome Due to Pegfilgrastim.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients receiving dose-dense chemotherapy, adverse effects such as neutropenia can be reduced by colony-stimulating factors. Pegfilgrastim, a colony-stimulating factor, has associated adverse effects, including bone pain, fever, and, rarely, hyperleukocytosis. We describe a 45-year-old woman with breast cancer receiving dose-dense Adriamycin and cyclophosphamide chemotherapy. She presented with hyperleukocytosis after receiving pegfilgrastim, which resulted in hospitalization. This case report reviews the strategy to minimize the risk of hyperleukocytosis from pegfilgrastim administered in dose-dense chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.